Preclinical study results demonstrated that intradiscal injection of Discogenic Cells, the active ingredient in DiscGenics’ IDCT allogeneic cell therapy, may be a viable treatment for degenerative disc disease. The cells produce an extracellular matrix that may rebuild depleting tissue within the discs.
Earlier this month, DiscGenics announced that the first 30 subjects have been safely treated in its first-in-human 60-patient U.S. clinical study of IDCT. An independent data safety monitoring committee reported no safety issues, and recommended that the trial continue with no changes to the protocol.
Sources: DiscGenics, Inc.; ORTHOWORLD
Preclinical study results demonstrated that intradiscal injection of Discogenic Cells, the active ingredient in DiscGenics' IDCT allogeneic cell therapy, may be a viable treatment for degenerative disc disease. The cells produce an extracellular matrix that may rebuild depleting tissue within the discs.
Earlier this month, DiscGenics announced...
Preclinical study results demonstrated that intradiscal injection of Discogenic Cells, the active ingredient in DiscGenics’ IDCT allogeneic cell therapy, may be a viable treatment for degenerative disc disease. The cells produce an extracellular matrix that may rebuild depleting tissue within the discs.
Earlier this month, DiscGenics announced that the first 30 subjects have been safely treated in its first-in-human 60-patient U.S. clinical study of IDCT. An independent data safety monitoring committee reported no safety issues, and recommended that the trial continue with no changes to the protocol.
Sources: DiscGenics, Inc.; ORTHOWORLD
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.